Overall rank by patents
#5,615
Across all tracked assignees
USPTO PatentsView assignee record - 61 granted patents across 11 technology areas, active 2015–2022. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61J (CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES ).
The verdict
Neomed holds 61 US patents across 11 technology areas, rank #5,615 of 50,000 tracked assignees.
Neomed, Inc. has been granted 61 US utility patents between 2015 and 2022, placing Neomed, Inc. at rank #5,615 across all assignees tracked by PlainPatent. This portfolio spans 11 distinct Cooperative Patent Classification (CPC) subclasses, averaging 11.0 claims per patent with primary concentration in A61J (CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES ). As a US Corporation, Neomed, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Neomed sits between Nibco Inc. (61 patents, rank #5,611) and Pruitt TOOL & Supply Co. (61 patents, rank #5,619) - the closest US assignees by grant volume. The composite Innovation Score of 32.8/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 29 grants, compared with 32 in the 2015–2019 window, a -9% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Neomed, Inc.'s 11.0 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while concentration in 11 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Neomed, Inc. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
NIBCO Inc.
61 patents
NICO Corporation
61 patents
NINGBO TUOTUO RIVER DESIGN COMPANY
61 patents
NOXELL CORPORATION
61 patents
Noritake Co., Limited
61 patents
OP Solutions, LLC
61 patents
PAUL WURTH S.A.
61 patents
PRUITT TOOL & SUPPLY CO.
61 patents
NeoMed, Inc.
61 patents
What this shows Neomed holds 61 patents at rank #5,615, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #5,615 in granted patent volume.
Other assignees with the most granted patents in Neomed's primary technology class.
Neomed's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
33 Top 58% higher than 42% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 3 | 4.9% |
| 2016 | 5 | 8.2% |
| 2017 | 8 | 13.1% |
| 2018 | 10 | 16.4% |
| 2019 | 6 | 9.8% |
| 2020 | 21 | 34.4% |
| 2021 | 7 | 11.5% |
| 2022 | 1 | 1.6% |
Top 11 of 11 technology areas
Overall rank by patents
#5,615
Across all tracked assignees
32.8 out of 100
How to use this portfolio
Neomed's 61 grants land it in the top 58% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.